FDA lifts hold on Rocket’s pivotal study for its gene therapy, which is now a lower dose

The FDA gave Rocket Pharmaceuticals the green light to resume a clinical trial of its gene therapy for Danon disease, a rare genetic disorder that affects multiple organs, including the heart. Rocket is